Compare FLXS & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FLXS | FHTX |
|---|---|---|
| Founded | 2001 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Home Furnishings | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 290.6M | 323.4M |
| IPO Year | 1995 | 2020 |
| Metric | FLXS | FHTX |
|---|---|---|
| Price | $76.89 | $5.57 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | ★ $54.00 | $11.50 |
| AVG Volume (30 Days) | 37.0K | ★ 242.3K |
| Earning Date | 04-20-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.41% | N/A |
| EPS Growth | N/A | ★ 25.32 |
| EPS | ★ 3.63 | N/A |
| Revenue | ★ $441,073,000.00 | $30,909,000.00 |
| Revenue This Year | $4.51 | $8.89 |
| Revenue Next Year | $4.89 | $20.13 |
| P/E Ratio | $21.31 | ★ N/A |
| Revenue Growth | N/A | ★ 36.75 |
| 52 Week Low | $32.65 | $3.27 |
| 52 Week High | $79.70 | $6.95 |
| Indicator | FLXS | FHTX |
|---|---|---|
| Relative Strength Index (RSI) | N/A | N/A |
| Support Level | N/A | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
Flexsteel Industries Inc is a United States-based company that manufactures, imports, and markets residential upholstered wooden furniture products. Its product offerings include sofas, loveseats, chairs, rockers, desks, tables, convertible bedding units, and bedroom furniture. The company's products are intended for use in home, office, hotel, healthcare, and other contract applications. A featured component in the company's upholstered furniture is the durable Blue Steel Spring. It operates in the business segment of Furniture products. The company's furniture products business involves the distribution of manufactured and imported products for residential markets.
Foghorn Therapeutics Inc is a clinical stage, precision therapeutics biotechnology company focused on pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system. Its proprietary platform is designed to provide an integrated, mechanistic understanding of interactions within the chromatin regulatory system, supporting the identification and validation of potential therapeutic targets. The company's flagship program is FHD-909.